Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | APEX1 | P27695 | 2/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | TTR | P02766 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.69 |
| ▸ | THRB | P10828 | 2/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | BLM | P54132 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Emodic Acid SCHEMBL29360148 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTTDP1MEN1POLB | |
| Emodic Acid SCHEMBL5073381 | 0.89 | ALDH1A1 (0.80) | ALDH1A1MAPTTDP1MEN1POLB | |
| SCHEMBL16225641 | 0.85 | ALDH1A1 (0.73) | ALDH1A1MAPTTDP1MEN1POLB | |
| SCHEMBL29390162 | 0.84 | ESR1 (0.77) | ALDH1A1MAPTTDP1MEN1POLB | |
| SCHEMBL5968219 | 0.84 | ESR1 (0.77) | ALDH1A1MAPTTDP1MEN1POLB | |
| SCHEMBL23486220 | 0.84 | ALDH1A1 (0.73) | ALDH1A1MAPTTDP1MEN1POLB | |
| SCHEMBL5073503 | 0.83 | MEN1 (0.71) | ALDH1A1MAPTTDP1MEN1POLB | |
| SCHEMBL18601968 | 0.83 | ALDH1A1 (0.71) | ALDH1A1MAPTTDP1MEN1POLB | |
| SCHEMBL18048116 | 0.83 | ALDH1A1 (0.71) | ALDH1A1MAPTTDP1MEN1POLB | |
| SCHEMBL16225652 | 0.82 | ALDH1A1 (0.69) | ALDH1A1MAPTTDP1MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3943085-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2022-01-26 | — | — | EP | claimed |
| US-20210186947-A1 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH ZURICH (CH) | 2021-06-24 | — | — | US | claimed |
| EP-3801507-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2021-04-14 | — | — | EP | claimed |
| EP-3943085-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2022-01-26 | — | — | EP | disclosed |
| US-20210186947-A1 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH ZURICH (CH) | 2021-06-24 | — | — | US | disclosed |
| WO-2021110177-A1 | RHEIN DERIVATIVE AND ANTIVIRAL USE THEREOF | 中检科医药科技(北京)集团有限公司 | 2021-06-10 | — | — | WO | disclosed |
| EP-3801507-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2021-04-14 | — | — | EP | disclosed |
| CN-105106981-B | Dianthranide quinones application in preparation of anti-tumor drugs | 江苏省中医药研究院 | 2018-12-28 | — | — | CN | disclosed |
| EP-1913940-B1 | RHEIN CONJUGATES, PREPARATION METHOD THEREOF AND THEIR USES IN PRODUCING MEDICINES FOR TREATING DIABETIC NEPHROSIS, INTESTINAL ADHESION AND OSTEOARTHRITIS | CONG XIAODONG (CN) | 2018-11-21 | — | — | EP | disclosed |
| US-20180280321-A1 | COMPOSITIONS AND METHODS THAT INHIBIT QUORUM SENSING | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2018-10-04 | — | — | US | disclosed |
| WO-2016145279-A2 | COMPOSITIONS AND METHODS THAT INHIBIT QUORUM SENSING | STC.UNM (US) | 2016-09-15 | — | — | WO | disclosed |
| CN-1899277-B | Composition of rheinic acid or rheinic acid compounds, its preparing method and its use in preparing medicine for treating diabetic nephrosis | NANJING ZHONGJING MEDICINE SCIENCE TECHNOLOGY RES INST | 2013-12-18 | — | — | CN | disclosed |
| CN-1899275-B | Use of composition of rheinic acid or rheinic acid compounds in preparing medicine for treating osteoarthritis | LIANCHUAN MEDICINE TECHNOLOGY CO LTD JIANGSU | 2013-11-27 | — | — | CN | disclosed |
| US-20080207758-A1 | Reaction product of rhein with bases or amino acids; antidiabetic agents; gastrointestinal disorders; antiarthritic agents | CONG XIAODONG | 2008-08-28 | — | — | US | disclosed |
| EP-1913940-A1 | RHEIN CONJUGATES, PREPARATION METHOD THEREOF AND THEIR USES IN PRODUCING MEDICINES FOR TREATING DIABETIC NEPHROSIS, INTESTINAL ADHESION AND OSTEOARTHRITIS | Jiangsu Lianchuang Pharmaceutical Technology Co. (CN) | 2008-04-23 | — | — | EP | disclosed |
| CN-1899275-A | Composition of rheinic acid or rheinic acid compounds, its preparing method and its use in preparing medicine for treating osteoarthritis | LIANCHUAN MEDICINE TECHNOLOGY (CN) | 2007-01-24 | — | — | CN | disclosed |
| CN-1899277-A | Composition of rheinic acid or rheinic acid compounds, its preparing method and its use in preparing medicine for treating diabetic nephrosis | LIANCHUANG MEDICINE TECHNOLOGY (CN) | 2007-01-24 | — | — | CN | disclosed |
| CN-1899276-A | Composition of rheinic acid or rheinic acid compounds, its preparing method and its use in preparing medicine for preventing intestinal adhesion | LIANCHUAN MEDICINE TECHNOLOGY (CN) | 2007-01-24 | — | — | CN | disclosed |
| US-20060100154-A1 | Long-acting gonadotropin-releasing hormone analogs and methods of use thereof | YEDA RESEARCH AND DEVELOPMENT CO (US) | 2006-05-11 | — | — | US | disclosed |
| WO-2004030687-A1 | LONG-ACTING GONADOTROPIN-RELEASING HORMONE ANALOGS AND METHODS OF USE THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100154-A1 | Long-acting gonadotropin-releasing hormone analogs and methods of use thereof | GNRHR, FSHR, GHRHR | ALDH1A1 3602/4885MAPT 4802/4885TDP1 3572/4885 |
| US-20080207758-A1 | Reaction product of rhein with bases or amino acids; antidiabetic agents; gastrointestinal disorders; antiarthritic agents | ARGLU1, RO60, CROCC | ALDH1A1 3432/4885MAPT 3631/4885TDP1 4618/4885 |
| US-20210186947-A1 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | TOMM70, TOMM34, TIMM50 | ALDH1A1 3685/4885MAPT 2071/4885TDP1 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.